ECP 2022 Final Programme

217 ECP 2022 Basel Agenda 13:00 – 13:05 Welcome and introductions Lukas Bubendorf 13:05 – 13:25 Keeping up with the evolving PD-L1 landscape Arndt Hartmann 13:25 – 13:45 Panel discussion: New kids on the block - Recent PD-L1 indications and practical considerations for scoring Lukas Bubendorf/Faculty 13:45 – 13:55 Discussion and Q&A Faculty 13:55 – 14:15 The increasing relevance of MSI/MMR testing in oncology Paula Borralho Nunes 14:15 – 14:25 Discussion and Q&A Faculty 14:25 – 14:30 Closing remarks Lukas Bubendorf Chair Lukas Bubendorf Head of Cytopathology University Hospital Basel Institute of Medical Genetics and Pathology Basel, Switzerland Faculty Arndt Hartmann Institute of Pathology Friedrich-Alexander- University Erlangen-Nürnberg University Hospital Erlangen, Germany Paula Borralho Nunes Director of Cuf Oncology and Faculty of Medicine University of Lisbon Lisbon, Portugal Agenda may be subject to change pending speaker confirmation Sunday, 04 September 2022 13:00 – 14:30 (CET) Exploration of actionable biomarkers in determining eligibility for immunotherapy Satellite symposium at ECP sponsored by MSD Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. HQ-NON-00771 09/22 214094-2